Neuroendocrine Prostate Cancer Market And Pipeline Appear Robust With Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight. The Neur ...

EDAP TMS reported Q2 2023 revenues of $15.52 million, a 0.9% YoY growth that missed estimates. In Q2 2023, HIFU’s total revenue growth stood at 63.6% (YoY). The procedure growth of Focal One shot up ...

This promising new application for Remplir can potentially reduce post-surgical complications from peripheral nerve injury, representing a globally significant commercial opportunity for the Company.

ASX-listed healthcare companies are advancing new approaches to prostate cancer, spanning imaging, targeted therapies and surgical nerve repair. ... Read More The post ASX healthcare stocks advance ...

MINNEAPOLIS, April 21, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company based in Maple Grove, Minn., today announced that Aaron Milbank, MD., of Minnesota Urology ...

Exact Imaging is looking to broaden uptake of its high-resolution micro-ultrasound system for prostate cancer screening and is boosting its commercial team to help. The company markets ExactVu, a ...

Some of the biggest NFL stars are coming together to share an important message about men’s health. During the 2026 Super Bowl on Sunday (February 8), Novartis AG, a multinational pharmaceutical ...

Johnson & Johnson (NYSE:JNJ) has presented Phase 1 clinical trial results for JNJ-6143, an investigational oral treatment for advanced prostate cancer, at the European Society for Medical Oncology ...

Although the use of tissue-based gene expression testing for prostate cancer was found to be “highly variable in the United States at the regional level,” distinct regional trajectories of commercial ...